Article
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
British journal of haematology - 1 Nov 2018
Jain Preetesh, Kanagal-Shamanna Rashmi, Zhang Shaojun, Ahmed Makhdum, Ghorab Ahmad, Zhang Liang, Ok Chi Young, Li Shaoying, Hagemeister Frederick, Zeng Dongfeng, Gong Tiejun, Chen Wendy, Badillo Maria, Nomie Krystle, Fayad Luis, Medeiros Leonard J, Neelapu Sattva, Fowler Nathan, Romaguera Jorge, Champlin Richard, Wang Linghua, Wang Michael L
Abstract excerpt
Long term outcomes and mutations in patients with mantle cell lymphoma (MCL) who discontinued ibrutinib have not been described. Using deep targeted next generation sequencing, we performed somatic mutation profiling from 15 MCL patients (including 5 patients with paired samples; before and after progression on ibrutinib). We identified 80 patients with MCL who discontinued ibrutinib therapy for various reasons....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.